Selective elimination of immunosuppressive T cells in patients with multiple myeloma.

Adult Aged Animals Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents / therapeutic use Apoptosis Cell Proliferation Female Humans Lymphocyte Depletion / methods Male Mice Mice, Inbred NOD Mice, SCID Middle Aged Multiple Myeloma / immunology Prognosis Signaling Lymphocytic Activation Molecule Family / genetics Tumor Cells, Cultured Xenograft Model Antitumor Assays

Journal

Leukemia

ISSN: 1476-5551

Titre abrégé: Leukemia

Pays: England

ID NLM: 8704895

Informations de publication

Date de publication:
09 2021

Historique:

received: 13 10 2020

accepted: 28 01 2021

revised: 13 01 2021

pubmed: 19 2 2021

medline: 6 10 2021

entrez: 18 2 2021

Statut: ppublish

Résumé

Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8

Identifiants

DOI: 10.1038/s41375-021-01172-x PMID: 33597728 PMC: PMC8410603

pubmed: 33597728

doi: 10.1038/s41375-021-01172-x

pii: 10.1038/s41375-021-01172-x

pmc: PMC8410603

doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0

Antineoplastic Agents 0

SLAMF7 protein, human 0

Signaling Lymphocytic Activation Molecule Family 0

elotuzumab 1351PE5UGS

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

2602-2615

Informations de copyright

Références

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252–62.

pubmed: 29257139 doi: 10.1038/leu.2017.329

Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676–81.

pubmed: 28061985 pmcid: 5283695 doi: 10.1053/j.seminoncol.2016.11.004

Boles KS, Mathew PA. Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics. 2001;52:302–7.

pubmed: 11220635 doi: 10.1007/s002510000274

Boles KS, Stepp SE, Bennett M, Kumar V, Mathew PA. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev. 2001;181:234–49.

pubmed: 11513145 doi: 10.1034/j.1600-065X.2001.1810120.x

Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–84.

pubmed: 18451245 pmcid: 4433038 doi: 10.1158/1078-0432.CCR-07-4246

Lee JK, Boles KS, Mathew PA. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol. 2004;34:2791–9.

pubmed: 15368295 doi: 10.1002/eji.200424917

Xie Z, Gunaratne J, Cheong LL, Liu SC, Koh TL, Huang G, et al. Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. Oncotarget. 2013;4:1008–18.

pubmed: 23900284 pmcid: 3759662 doi: 10.18632/oncotarget.1049

Tai Y-T, Soydan E, Song W, Fulciniti M, Kim K, Hong F, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009;113:4309–18.

pubmed: 19196658 pmcid: 2676088 doi: 10.1182/blood-2008-10-183772

Mateos M-V, Granell M, Oriol A, Martinez-Lopez J, Blade J, Hernandez MT, et al. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016;175:448–56.

pubmed: 27434748 doi: 10.1111/bjh.14263

Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Lancet Haematol. 2015;2:e516–27.

pubmed: 26686406 pmcid: 6871650 doi: 10.1016/S2352-3026(15)00197-0

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–31.

pubmed: 26035255 doi: 10.1056/NEJMoa1505654

Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178:896–905.

pubmed: 28677826 pmcid: 6084289 doi: 10.1111/bjh.14787

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–22.

pubmed: 30403938 doi: 10.1056/NEJMoa1805762

Pazina T, James AM, MacFarlane AW, Bezman NA, Henning KA, Bee C, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology. 2017;6:e1339853.

pubmed: 28932638 pmcid: 5599094 doi: 10.1080/2162402X.2017.1339853

Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol, Immunother CII. 2013;62:1841–9.

pubmed: 24162108 doi: 10.1007/s00262-013-1493-8

Balasa B, Yun R, Belmar NA, Fox M, Chao DT, Robbins MD, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol, Immunother. 2014;64:61–73.

doi: 10.1007/s00262-014-1610-3

Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, et al. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Adv. 2017;1:753–65.

pubmed: 29296719 pmcid: 5728054 doi: 10.1182/bloodadvances.2017004382

Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood. 2017;130:2838–47.

pubmed: 29089311 doi: 10.1182/blood-2017-04-778423

Tassi I, Colonna M. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase C signaling pathways in human NK cells. J Immunol. 2005;175:7996–8002.

pubmed: 16339536 doi: 10.4049/jimmunol.175.12.7996

Filaci G, Fravega M, Fenoglio D, Rizzi M, Negrini S, Viggiani R, et al. Non-antigen specific CD8+ T suppressor lymphocytes. Clin Exp Med. 2004;4:86–92.

pubmed: 15672945 doi: 10.1007/s10238-004-0042-3

Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol. 2007;179:4323–34.

pubmed: 17878327 doi: 10.4049/jimmunol.179.7.4323

Plaumann J, Engelhardt M, Awwad MHS, Echchannaoui H, Amman E, Raab MS, et al. IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells. Cancer Immunol, Immunother CII. 2018;67:1695–707.

pubmed: 30128739 doi: 10.1007/s00262-018-2230-0

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, et al. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer. 2019;19:504.

pubmed: 31138244 pmcid: 6537200 doi: 10.1186/s12885-019-5600-x

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, et al. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncoimmunology. 2018;7:e1486356.

pubmed: 30288348 pmcid: 6169592 doi: 10.1080/2162402X.2018.1486356

Granzow M, Hegenbart U, Hinderhofer K, Hose D, Seckinger A, Bochtler T, et al. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis. Haematologica. 2017;102:1281–90.

pubmed: 28341732 pmcid: 5566044 doi: 10.3324/haematol.2016.160721

Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, et al. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am J Hematol. 2016;91:E473–7.

pubmed: 27508939 doi: 10.1002/ajh.24533

Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia. 2017;31:1363–7.

pubmed: 28017969 doi: 10.1038/leu.2016.384

Busch L, Mougiakakos D, Büttner-Herold M, Müller MJ, Volmer DA, Bach C, et al. Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway. Leukemia. 2018;32:2445–58.

pubmed: 29654274 doi: 10.1038/s41375-018-0114-0

Echchannaoui H, Petschenka J, Ferreira EA, Hauptrock B, Lotz-Jenne C, Voss R-H, et al. A potent tumor-reactive p53-specific single-chain TCR without on- or off-target autoimmunity in vivo. Mol Ther. 2018;27:261–71.

pubmed: 30528087 pmcid: 6319330 doi: 10.1016/j.ymthe.2018.11.006

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma. 2013;29:15–21.

doi: 10.1093/bioinformatics/bts635

Tarasov A, Vilella AJ, Cuppen E, Nijman IJ, Prins P. Sambamba: fast processing of NGS alignment formats. Bioinformatics. 2015;31:2032–4.

pubmed: 25697820 pmcid: 4765878 doi: 10.1093/bioinformatics/btv098

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.

pubmed: 19505943 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352

DeLuca DS, Levin JZ, Sivachenko A, Fennell T, Nazaire M-D, Williams C, et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics. 2012;28:1530–2.

pubmed: 22539670 pmcid: 3356847 doi: 10.1093/bioinformatics/bts196

Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–30.

pubmed: 24227677 doi: 10.1093/bioinformatics/btt656

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.

pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8

Zhu A, Ibrahim JG, Love MI Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics. 2018.

Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics J Integr Biol. 2012;16:284–7.

doi: 10.1089/omi.2011.0118

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–25.

pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004

Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38:20–28.

pubmed: 27793572 doi: 10.1016/j.it.2016.10.002

Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, et al. TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood. 2018;132:1689–94.

pubmed: 29986909 doi: 10.1182/blood-2018-01-825265

Minnie SA, Kuns RD, Gartlan KH, Zhang P, Wilkinson AN, Samson L, et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood. 2018;132:1675–88.

pubmed: 30154111 doi: 10.1182/blood-2018-01-825240

Martinez GJ, Pereira RM, Äijö T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8

pubmed: 25680272 pmcid: 4346317 doi: 10.1016/j.immuni.2015.01.006

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.

pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102

Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, et al. Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells. Oncotarget. 2017;8:98200–14.

pubmed: 29228683 pmcid: 5716723 doi: 10.18632/oncotarget.21516

Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol. 2006;34:486–96.

pubmed: 16569595 pmcid: 1913933 doi: 10.1016/j.exphem.2006.01.008

Herrero AB, García-Gómez A, Garayoa M, Corchete LA, Hernández JM, San Miguel J, et al. Effects of IL-8 up-regulation on cell survival and osteoclastogenesis in multiple myeloma. Am J Pathol. 2016;186:2171–82.

pubmed: 27301357 doi: 10.1016/j.ajpath.2016.04.003

Gadó K, Domján G, Hegyesi H, Falus A. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Cell Biol Int. 2000;24:195–209.

pubmed: 10816321 doi: 10.1006/cbir.2000.0497

Rosean TR, van Tompkins S, Tricot G, Holman CJ, Olivier AK, Zhan F, et al. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014;59:188–202.

pubmed: 24845460 pmcid: 4209159 doi: 10.1007/s12026-014-8528-x

Shi G, Han J, Liu G, Hao Y, Ma Y, Li T, et al. Expansion of activated regulatory T cells by myeloid-specific chemokines via an alternative pathway in CSF of bacterial meningitis patients. Eur J Immunol. 2014;44:420–30.

pubmed: 24155161 doi: 10.1002/eji.201343572

Pérez-Quintero L-A, Roncagalli R, Guo H, Latour S, Davidson D, Veillette A. EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization. J Exp Med. 2014;211:727–42.

pubmed: 24687958 pmcid: 3978279 doi: 10.1084/jem.20132038

Cruz-Munoz M-E, Dong Z, Shi X, Zhang S, Veillette A. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol. 2009;10:297–305.

pubmed: 19151721 doi: 10.1038/ni.1693

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698–704.

pubmed: 27269947 pmcid: 5019749 doi: 10.1200/JCO.2015.65.9789

Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality? Blood. 2017;129:275–9.

pubmed: 27919908 doi: 10.1182/blood-2016-08-731885

Chen J, Zhong M-C, Guo H, Davidson D, Mishel S, Lu Y, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature. 2017;544:493–7.

pubmed: 28424516 pmcid: 5565268 doi: 10.1038/nature22076

He Y, Bouwstra R, Wiersma VR, Jong M, de, Jan Lourens H, Fehrmann R, et al. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. Nat Commun. 2019;10:533.

pubmed: 30710089 pmcid: 6358615 doi: 10.1038/s41467-018-08013-z

Casado JG, Soto R, DelaRosa O, Peralbo E, del Carmen Muñoz-Villanueva M, Rioja L, et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol, Immunother. 2005;54:1162–71.

doi: 10.1007/s00262-005-0682-5

Meloni F, Morosini M, Solari N, Passadore I, Nascimbene C, Novo M, et al. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol. 2006;67:1–12.

pubmed: 16698419 doi: 10.1016/j.humimm.2005.11.005

Okada T, Iiai T, Kawachi Y, Moroda T, Takii Y, Hatakeyama K, et al. Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer. Clin Exp Immunol. 1995;102:159–66.

pubmed: 7554383 pmcid: 1553343 doi: 10.1111/j.1365-2249.1995.tb06650.x